Thursday, 18 April 2024
Trending

[the_ad_group id="2845"]

Business News

Strong Buy Rating for Stoke Therapeutics’ STK-001 Backed by Positive KOL Feedback and Revolutionary Potential in Dravet Syndrome Treatment

Prelude Therapeutics management to meet virtually with Jefferies

[the_ad id="21475"]

[ad_1]

Leerink Partners analyst Rudy Li has maintained their bullish stance on STOK stock, giving a Buy rating on March 26.

Rudy Li has given his Buy rating due to a combination of factors that underscore the potential of Stoke Therapeutics’ STK-001 as a transformative therapy for Dravet syndrome. After conducting an investor pulse call with key opinion leaders (KOLs), the feedback was overwhelmingly positive, with both pediatric and adolescent/adult experts expressing confidence in the impressive seizure reductions observed with the 70mg dose of STK-001. Additionally, the maintenance doses (30/45mg every four months) showed promising non-seizure benefits. The KOLs also conveyed a sense of comfort with the safety profile of the drug, acknowledging the substantial unmet need for a Disease Modifying Therapy (DMT) in this space and expressing a desire to utilize STK-001 for the majority of their patients.
The optimism displayed by the medical experts aligns with Rudy Li’s bullish perspective on the drug’s potential to revolutionize the treatment paradigm for Dravet syndrome. Despite a significant uptick in the stock price following the recent data release, Li believes that the market has not fully appreciated the drug’s potential and anticipates further upward movement as more investors recognize its blockbuster possibility. Leerink Partners anticipates more updates from Stoke Therapeutics later in the year, which should provide additional clarity on the pivotal trial design and serve as another key de-risking event for the stock. Li’s Outperform rating on STOK is maintained with the expectation of continued positive developments.

In another report released on March 26, H.C. Wainwright also reiterated a Buy rating on the stock with a $35.00 price target.

Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is neutral on the stock.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Stoke Therapeutics (STOK) Company Description:

Stoke Therapeutics, Inc. engages in the research and development of treatments for genetic diseases. It is a biotechnology firm that focuses to increase gene expression to treat severe genetic diseases, including genetic conditions…

Click Here to Read the Full Original Article at TipRanks Financial Blog…

[ad_2]

[the_ad id="21476"]